COVID-19 Testing for the Essential Workforce
Learn about our efforts to test people on the front line and how you can help.
Individuals who carry the KRAS-variant are at greater risk of developing breast, ovarian, and lung cancers. Recent studies also show women with this marker are up to eleven times as likely to develop a second, independent breast cancer. The overall goal of this study is to determine how to prevent multiple primary cancers in patients with the KRAS-variant.
We believe that management strategies applied during a first breast cancer diagnosis may change the risk of a second breast cancer for women with the KRAS-variant. Management strategies may include hormone therapies (e.g., tamoxifen, arimidex, etc.), surgery (e.g., preventive mastectomy), and chemotherapy.
In this study we will investigate two things, first, how common a family history of multiple primary cancers is for people with the KRAS-variant, and second, for women with breast cancer, which strategy for breast cancer management is safest for women with the KRAS-variant. (Note: a second, independent breast cancer is not the same as a recurrence of the first breast cancer.)
Apply to Participate!
Once you submit your survey, here is what you can expect: